Eli Lilly upgraded at HSBC after latest trial win for obesity pill
Source: SeekingAlpha
2025-08-27 09:05:01 ET
More on Eli Lilly
- Eli Lilly Vs. Novo Nordisk: One Stock Is Massively Undervalued, The Other Overvalued
- Pharmaceuticals Industry Analysis: Eli Lilly Tops My Tier Two
- Novo Nordisk's Loss Is Eli Lilly's Gain, And Vice Versa
- Eli Lilly says Verzenio extended survival in late-stage breast cancer trial
- Chugai spikes after Eli Lilly trial win for obesity pill
Read the full article on Seeking Alpha
For further details see:
Eli Lilly upgraded at HSBC after latest trial win for obesity pill
Chugai Pharmaceutical
NASDAQ: CHGCF
CHGCF Trading
2.33% G/L:
$60.89 Last:
573 Volume:
$60.89 Open:
